| 罗格列酮对糖尿病肾病患者尿单核细胞趋化蛋白-1的影响 |
| |
| 引用本文： | 黄晓霞,张建鄂,李雪锋,李涛.罗格列酮对糖尿病肾病患者尿单核细胞趋化蛋白-1的影响[J].郧阳医学院学报,2006,25(4):211-213. |
| |
| 作者姓名： | 黄晓霞 张建鄂 李雪锋 李涛 |
| |
| 作者单位： | [1]郧阳医学院内科学教研室,湖北十堰442000 [2]郧阳医学院附属太和医院肾内科,湖北十堰442000 [3]郧阳医学院内分泌科,湖北十堰442000 |
| |
| 摘 要： | 目的:探讨罗格列酮对糖尿病肾病(DN)患者尿单核细胞趋化蛋白-1(MCP-1)的影响及其对DN治疗的作用机制。方法:78例2型DN(Ⅲ期)患者随机分为两组,对照组给予常规治疗,治疗组在常规治疗基础上服用罗格列酮4mg日/,疗程12周。治疗前后分别采用ELISA法和放免法检测尿MCP-1和24h尿白蛋白含量,计算尿白蛋白排泄率(UAER)及内生肌酐清除率(Ccr)。结果:治疗组尿MCP-1、UAER均下降,Ccr明显升高(P<0.05),对照组无改变(P>0.05)。结论:罗格列酮可能通过抑制炎症反应而减轻微量白蛋白尿、改善肾功能。
|
| 关 键 词： | 罗格列酮 糖尿病肾病 MCP-1 |
| 文章编号： | 1006-9674（2006）04-0211-03 |
| 收稿时间： | 2006-05-11 |
| 修稿时间： | 2006年5月11日 |
Effect of Rosiglitazone on Urinary Monocyte Chemoattractant Protein-1 in Patients with Diabetic Nephropathy |
| |
| HUANG Xiao-xia,ZHANG Jia-ne,LI Xue-feng,LI Tao.Effect of Rosiglitazone on Urinary Monocyte Chemoattractant Protein-1 in Patients with Diabetic Nephropathy[J].Journal of Yunyang Medical College,2006,25(4):211-213. |
| |
| Authors: | HUANG Xiao-xia ZHANG Jia-ne LI Xue-feng LI Tao |
| |
| Abstract: | Objective To study the effect of rosiglitazone on urinary monocyte chemoattractant protein-1 in patients with diabetic nephropathy and explore the mechanism of rosiglitazone on DN.Methods Seventy-eight type 2 diabetic patients with diabetic nephropathy(Ⅲ stage) were randomly divided into two groups:the treated group(n=39) and the control group(n=39).All patients were treated with routine therapy,and the patients in treated group were treated with rosiglitazone 4mg/d additionally for twelve weeks.Urinary MCP-1 were assayed by ELISA.Results Urinary MCP-1 of patients in treated group were singnificently decreased at the end of treatment compared with those in control group(P<0.05).Conclusion Rosiglitazone can improve the renal founction by inflammatory inhibition through decreasing urinary MCP-1. |
| |
| Keywords: | MCP-1 |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
